Home Tools
Log in
Cart

VDA

Vascular disrupting agents (VDAs), anti-cancer drugs that target established tumor blood vessels, fall into two main classes: microtubule targeting drugs, exemplified by combretastatin A4 (CA4), and flavonoids, exemplified by 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Cat No. product name
T3112 Verteporfin Verteporfin, a benzoporphyrin derivative monoacid ring A, can inhibit the activity of YAP.
T6273 Vadimezan Vadimezan is a fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-...
Verteporfin
T3112
Verteporfin, a benzoporphyrin derivative monoacid ring A, can inhibit the activity of YAP.
Vadimezan
T6273
Vadimezan is a fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-...